Open challenges in magnetic drug targeting.
The principle of magnetic drug targeting, wherein therapy is attached to magnetically responsive carriers and magnetic fields are used to direct that therapy to disease locations, has been around for nearly two decades. Yet our ability to safely and effectively direct therapy to where it needs to go, for instance to deep tissue targets, remains limited. To date, magnetic targeting methods have not yet passed regulatory approval or reached clinical use. Below we outline key challenges to magnetic targeting, which include designing and selecting magnetic carriers for specific clinical indications, safely and effectively reaching targets behind tissue and anatomical barriers, real-time carrier imaging, and magnet design and control for deep and precise targeting. Addressing these challenges will require interactions across disciplines. Nanofabricators and chemists should work with biologists, mathematicians, and engineers to better understand how carriers move through live tissues and how to optimize carrier and magnet designs to better direct therapy to disease targets. Clinicians should be involved early on and throughout the whole process to ensure the methods that are being developed meet a compelling clinical need and will be practical in a clinical setting. Our hope is that highlighting these challenges will help researchers translate magnetic drug targeting from a novel concept to a clinically available treatment that can put therapy where it needs to go in human patients.
Fischell Department of Bioengineering, University of Maryland, College Park, MD, USA; Institute for Systems Research, University of Maryland, College Park, MD, USA.
Benjamin
B
Shapiro
Sandip
S
Kulkarni
Aleksander
A
Nacev
Silvia
S
Muro
Pavel Y
PY
Stepanov
Irving N
IN
Weinberg
D003692:Delayed-Action Preparations / Q000737:chemistry* / Q000528:radiation effects; D060526:Magnetic Fields; D058185:Magnetite Nanoparticles / Q000737:chemistry* / Q000528:radiation effects; D058990:Molecular Targeted Therapy / Q000379:methods*; D053769:Nanocapsules / Q000008:administration & dosage / Q000737:chemistry* / Q000528:radiation effects
D003692:Delayed-Action Preparations; D058185:Magnetite Nanoparticles; D053769:Nanocapsules